Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0...

FDA Drug Recall #D-0665-2024 — Class II — September 16, 2024

Recall Summary

Recall Number D-0665-2024
Classification Class II — Moderate risk
Date Initiated September 16, 2024
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm AbbVie Inc.
Location North Chicago, IL
Product Type Drugs
Quantity 763,426 tubes

Product Description

Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230312042

Reason for Recall

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Distribution Pattern

Nationwide in the USA, Foreign Consignees (Austrailia, Canada, Great Britain)

Lot / Code Information

Lot: 387489, Exp. Oct 24; 387490, Exp. Jun 25; 390422, Exp. Nov 24; 390424, Exp. Oct 24; 391692, Exp. Jun 25; 391893, Exp. Nov 25; 394822, Exp. Feb 26; 395991, Exp. Mar 26; 397905, 397973, 397974, Exp May 26; 399019, 399254, Exp. Jun 26; 399922, Exp. Jul 26; 408738, Exp. Mar 27; T3911, Exp. Sep 24; T4015, T4031, T4032, T4033, T4108, Exp. Oct 24.

Other Recalls from AbbVie Inc.

Recall # Classification Product Date
D-0551-2026 Class III PRED MILD, prednisolone acetate ophthalmic susp... May 18, 2026
D-0664-2024 Class II Refresh P.M., (Mineral Oil 42.5%, White Petrola... Sep 16, 2024
D-0088-2024 Class III Synthroid, Levothyroxine Sodium Tablets, USP 12... Oct 17, 2023
D-0412-2018 Class III Ultane (sevoflurane), 250 mL, Inhalation Anesth... Jan 22, 2018
D-0034-2018 Class III AndroGel (testosterone gel) 1.62%, 40.5mg in 2.... Sep 8, 2017

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.